Zimberelimab
- Generic Name
- Zimberelimab
- Drug Type
- Biotech
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies
- Conditions
- NeoplasmCancer, Malignant Tumors
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06759649
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸NEXT Oncology San Antonio, San Antonio, Texas, United States
🇺🇸START, San Antonio, Texas, United States
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06727565
- Locations
- 🇫🇷
CHU de Bordeaux, Pessac, France
🇮🇹Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Spain
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 154
- Registration Number
- NCT06532565
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Conditions
- Lung DiseasesCarcinoma, Non-Small-Cell LungResectable Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 129
- Registration Number
- NCT06431633
- Locations
- 🇪🇸
Hospital General de Elche, Elche, Alicante, Spain
🇪🇸ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
Peri-operative Zimberelimab vs Zimberelimab in Comb With Domvanalimab in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric & Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)
- Conditions
- Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 50
- Registration Number
- NCT06250036
- Locations
- 🇬🇧
Ninewells hospital and Medical School, Dundee, United Kingdom
🇬🇧The Royal Marsden NHSFT, London, United Kingdom
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
- Conditions
- Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-05-09
- Target Recruit Count
- 31
- Registration Number
- NCT06238921
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
- Conditions
- Previously AG Chemotherapy Treated Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT06166589
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06155396
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Beijing Obstetrics and Gynecology Hospital ,Capital Medical University, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
PeRioperative Immunotherapy Combined with Sacituzumab Govitecan in Muscle Invasive BlAdder Cancer
- Conditions
- Urothelial Bladder Carcinoma
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
- Target Recruit Count
- 70
- Registration Number
- NCT06133517
- Locations
- 🇪🇸
Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain
🇪🇸ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Hospital Duran i Reynals (ICO L´Hospitalet), L'Hospitalet De Llobregat, Barcelona, Spain
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
- Target Recruit Count
- 24
- Registration Number
- NCT06128460
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.